DNA 시퀀싱 시장 : 성장, 동향, 예측(2019-2024년)

※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 DNA 시퀀싱 시장은 2019-2024년간 18.9%의 연평균 복합 성장률(CAR)로 성장할 전망입니다.

세계의 DNA 시퀀싱(DNA Sequencing) 시장을 조사했으며, 시장 개요, 종류·용도·최종사용자·지역별 시장 동향, 시장 규모 추이와 예측, 시장 성장 촉진요인 및 저해요인, 시장 기회 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 서론

• 조사 성과
• 조사의 전제조건
• 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

• 시장 개요
• 성장 촉진요인
• 성장 저해요인
• Five Forces 분석
  • 신규 참여업체의 위협
  • 소비자의 협상력
  • 공급업체의 협상력
  • 대체 제품의 위협
  • 업계내 경쟁

제5장 시장 세분화

• 종류별
  • 기기
  • 소모품(키트, 시약)
  • 기타
• 플랫폼별
  • Sanger
  • 차세대 시퀀싱
  • 기타
• 용도별
  • 진단
  • 맞춤형 의료
  • 기타
• 최종사용자별
  • 병원/의료기관
  • 학술기관/연구기관
  • 의약품 기업/바이오테크놀러지 기업
  • 기타
• 지역별
  • 북미
  • 유럽
  • 아시아태평양
  • 중동 및 아프리카
  • 남미

제6장 경쟁 구도

• 기업 개요
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation(Beckman Coulter, Inc.)
  • Eurofins Scientific
  • F. Hoffmann-La Roche
  • Illumina, Inc.
  • Merck KGaA
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific, Inc.

제7장 시장 기회 및 향후 동향

The DNA sequencing market is projected to register a CAGR of 18.61% during the forecast period, with a revenue of approximately USD 8,712.10 million in 2020, and is expected to reach USD 24,257.75 million by 2026. The certain factors that are driving the market growth include the rise in technological advancements in DNA sequencing, increasing application in clinical diagnosis and drug discovery, and growing investment in R&D.

The COVID-19 pandemic has been showing a positive impact on the market studied, as this is increasing demand for DNA sequencing technology in the development of therapeutics and diagnostics. For instance, in August 2020, Helix COVID-19 NGS test has been authorized by FDA under an Emergency Use Authorization (EUA) for use only by Helix Laboratory, which is an amplicon-based next-generation sequencing (NGS) test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens from individuals suspected of COVID-19. Hence, the increasing DNA sequencing-based research and development activities in the development of diagnostic tools or effective therapeutics for COVID-19 is estimated that the market studied is likely to continue significant growth rate during the forecast period.

DNA sequencing has its application in diagnostics, personalized medicine, biomarkers, forensics, reproductive health, and other applications. The DNA sequencing technology holds great potential in clinical research and development of cancer diagnostics and therapeutics. Recently, the next-generation sequencing (NGS) technology has demonstrated the capacity as a high-throughput and an affordable approach in the identification and characterization of clinically actionable genetic variants across numerous genes at an exceptional speed in a single test. According to a research article by Hong-Yan Liu et al., published in Scientific Reports Journal 2019, it has been estimated that 80% of rare diseases are genetic in origin, and thus, genome sequencing-based diagnosis offers a promising alternative for rare-disease management, which is expected to show positive impact on the market studied. Therefore, the increasing application of DNA sequencing in clinical diagnosis and drug discovery is expected to drive the market growth over the forecast period.

The technological advancements in sequencing, from 2D sequencing in the 1970s to DNA sequencing, has come a long way. In recent years, platforms, such as Illumina/ Solexa, ABI/ SOLiD, 454/Roche, and Helicos, have provided unique prospects for high-throughput functional genomic research. Moreover, biologists and informatics experts have been focusing on the development of better genomes, one made possible by newer sequencing technologies, novel methods for locating sequences on chromosomes, and improved software for DNA sequencing.

In addition, the next-generation sequencing (NGS) technology has been gaining popularity as a routine clinical diagnostic test, particularly with the pandemic of COVID-19 infection, which shows positive impact on market. Thus, the increasing advancements in DNA sequencing technologies contributing to the growth of the market studied.

Key Market Trends

Next Generation Sequencing is Expected to Dominate the Market During the Forecasted Period

The next generation segment studied is being driven by factors such as the increasing applications of NGS, speed, cost, accuracy, efficient replacement of traditional technologies, and drug discovery applications demanding NGS technology. The advantage of this technology is that it is significantly cheaper, quicker, and needs significantly lesser DNA, which helps in the overall growth of the segment.

With the COVID-19 pandemic, there has been an increase in the adoption of next-generation sequencing technology in the diagnostics of infections owing to its high efficiency and accuracy. In June 2020, FDA issued an emergency use authorization to Ilumina Inc. for the product COVIDSeq Test, the first COVID-19 diagnostic test utilizing next-generation sequence technology. The advantage of using a next-generation sequencing test is that it can generate information about the genomic sequence of the virus present in a sample along with detecting the presence of the virus in the sample. This genomic information can be used for research purposes too, thus supporting the growth of the market.

There are various technological advancements in the field of medicine that are growing at a rapid pace and has led to the development of personalized medicine. There are a huge number of applications of next-generation sequencing in personalized medicine. Thus, the development of personalized medicine has opened many avenues for the application of NGS, which could accelerate the growth of the segment.

Along with the advantages and increasing demand for this technology, the launches and advancements are huge boosters to the segment growth. For instance, Thermo Fisher Scientific launched its Ion Torrent Genexus System in November 2019, the first fully integrated, next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that delivers results economically in a single day. Hence to the above-mentioned factors the segment is expected to grow during the given forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America dominated the market studied owing to the increase in funding and support activities by the government and non-government entities, especially in the United States. The increasing adoption of advanced technologies, and favourable support from the government and related policies, are primary driving factors for DNA sequencing in the country.

With the rising COVID-19, there is a positive impact on market growth. For instance, in April 2020, Genome Canada launched the Canadian COVID Genomics Network (CanCOGeN), a newly formed initiative backed by funding of USD 40 million. Led by Genome Canada, in partnership with the six regional Genome Centers, national and provincial public health labs, genome sequencing centres through CGEn, hospitals, universities and the private sector, CanCOGeN will scale up genomics-based COVID-19 research in Canada.

There are also various government bodies, like the US-based National Human Genome Research Institute (NHGRI), have been supporting research related to human genome sequencing, while funding research related to genome's structure, function, and role in health and disease. Moreover, these organizations support studies on ethical, legal, and social implications of the genome research.

In December 2020, Illumina Inc. and Harvard Pilgrim Health Care have announced a risk-sharing agreement to make whole-genome sequencing (WGS) available to certain Harvard Pilgrim members, effective January 2021. The program will leverage WGS to support faster diagnoses of genetic diseases in children, potentially eliminating the long, costly diagnostic process experienced by many families, with the goal of improving patient outcomes.

In November 2019, Thermo Fisher Scientific announced the launch of its Ion Torrent Genexus System, which is the first fully integrated, next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that delivers results economically in a single day. ​ Hence owing to these factors, the DNA sequencing market is expected to be one of the largest and is also expected to grow in the future.​

Competitive Landscape

The DNA Sequencing market is highly competitive and consists of a few major players. Companies like Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina Inc., Merck KGaA, Pacific Biosciences of California Inc., PerkinElmer Inc., and Thermo Fisher Scientific Inc., among others, hold a substantial share in the DNA Sequencing market. These companies are making efforts to address the rising consumer demand as well as making significant investments in production, distribution, and total quality management for the expansion of their portfolio.

Reasons to Purchase this report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rise in Technological Advancements in DNA Sequencing
  • 4.2.2 Increasing Application in Clinical Diagnosis and Drug Discovery
  • 4.2.3 Growing Investment in R&D
• 4.3 Market Restraints
  • 4.3.1 Interpretation of Complex Data and Lack of Skilled Professionals
  • 4.3.2 Legal and Ethical Issues
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 Product Type
  • 5.1.1 Instruments
  • 5.1.2 Consumables (Kits, Reagents)
  • 5.1.3 Other Product Types
• 5.2 Sequencing Type
  • 5.2.1 Sanger Sequencing
  • 5.2.2 Next Generation Sequencing
  • 5.2.3 Other Sequencing Types
• 5.3 By Application
  • 5.3.1 Diagnostics
  • 5.3.2 Personalized Medicine
  • 5.3.3 Other Applications
• 5.4 By End User
  • 5.4.1 Hospitals and Healthcare Organizations
  • 5.4.2 Academics and Research Institutions
  • 5.4.3 Pharmaceutical and Biotechnology Companies
  • 5.4.4 Other End Users
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.1.2 Canada (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.1.3 Mexico (Product Type, By Sequencing Type, By Application, and By End User)
  • 5.5.2 Europe
    • 5.5.2.1 Germany (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.2.2 United Kingdom (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.2.3 France (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.2.4 Italy (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.2.5 Spain (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.2.6 Rest of Europe (Product Type, By Sequencing Type, By Application, and By End User)
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.3.2 Japan (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.3.3 India (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.3.4 Australia (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.3.5 South Korea (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.3.6 Rest of Asia-Pacific (Product Type, By Sequencing Type, By Application, and By End User)
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.4.2 South Africa (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.4.3 Rest of Middle East and Africa (Product Type, By Sequencing Type, By Application, and By End User)
  • 5.5.5 South America
    • 5.5.5.1 Brazil (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.5.2 Argentina (Product Type, By Sequencing Type, By Application, and By End User)
    • 5.5.5.3 Rest of South America (Product Type, By Sequencing Type, By Application, and By End User)

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Agilent Technologies Inc.
  • 6.1.2 Bio-Rad Laboratories Inc.
  • 6.1.3 Danaher Corporation (Integrated DNA Technologies Inc.)
  • 6.1.4 F. Hoffmann-La Roche Ltd.
  • 6.1.5 Illumina, Inc.
  • 6.1.6 Merck KGaA
  • 6.1.7 PerkinElmer Inc.
  • 6.1.8 Thermo Fisher Scientific Inc.
  • 6.1.9 QIAGEN
  • 6.1.10 Macrogen, Inc.
  • 6.1.11 Myriad Genetics, Inc.
  • 6.1.12 Intrexon Bioinformatics Germany GmbH
  • 6.1.13 Eurofins Scientific
  • 6.1.14 Hamilton Thorne Biosciences
  • 6.1.15 Pacific Biosciences of California Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS